Neuroprotection by MAPK/ERK kinase inhibition with U0126 against oxidative stress in a mouse neuronal cell line and rat primary cultured cortical neurons

2000 ◽  
Vol 288 (2) ◽  
pp. 163-166 ◽  
Author(s):  
Takumi Satoh ◽  
Daisaku Nakatsuka ◽  
Yasuyoshi Watanabe ◽  
Izumi Nagata ◽  
Haruhiko Kikuchi ◽  
...  
Molecules ◽  
2018 ◽  
Vol 23 (8) ◽  
pp. 2010 ◽  
Author(s):  
Silvia Hilt ◽  
Robin Altman ◽  
Tamás Kálai ◽  
Izumi Maezawa ◽  
Qizhi Gong ◽  
...  

There is growing recognition regarding the role of intracellular amyloid beta (Aβ) in the Alzheimer’s disease process, which has been linked with aberrant signaling and the disruption of protein degradation mechanisms. Most notably, intraneuronal Aβ likely underlies the oxidative stress and mitochondrial dysfunction that have been identified as key elements of disease progression. In this study, we employed fluorescence imaging to explore the ability of a bifunctional small molecule to reduce aggregates of intracellular Aβ and attenuate oxidative stress. Structurally, this small molecule is comprised of a nitroxide spin label linked to an amyloidophilic fluorene and is known as spin-labeled fluorene (SLF). The effect of the SLF on intracellular Aβ accumulation and oxidative stress was measured in MC65 cells, a human neuronal cell line with inducible expression of the amyloid precursor protein and in the N2a neuronal cell line treated with exogenous Aβ. Super-resolution microscopy imaging showed SLF decreases the accumulation of intracellular Aβ. Confocal microscopy imaging of MC65 cells treated with a reactive oxygen species (ROS)-sensitive dye demonstrated SLF significantly reduces the intracellular Aβ-induced ROS signal. In order to determine the contributions of the separate SLF moieties to these protective activities, experiments were also carried out on cells with nitroxides lacking the Aβ targeting domain or fluorene derivatives lacking the nitroxide functionality. The findings support a synergistic effect of SLF in counteracting both the conformational toxicity of both endogenous and exogenous Aβ, its promotion of ROS, and Aβ metabolism. Furthermore, these studies demonstrate an intimate link between ROS production and Aβ oligomer formation.


2015 ◽  
Vol 40 (4) ◽  
pp. 854-863 ◽  
Author(s):  
Hong-Rui Zhao ◽  
Teng Jiang ◽  
You-Yong Tian ◽  
Qing Gao ◽  
Zhang Li ◽  
...  

2013 ◽  
Vol 77 (3) ◽  
pp. 446-454 ◽  
Author(s):  
Beata Kling ◽  
Daniel Bücherl ◽  
Peter Palatzky ◽  
Frank-Michael Matysik ◽  
Michael Decker ◽  
...  

2014 ◽  
Vol 31 ◽  
pp. 122
Author(s):  
K. Ando ◽  
K. Urakami ◽  
M. Kusuhara ◽  
S. Tamai ◽  
K. Yamaguchi ◽  
...  

Hypertension ◽  
2015 ◽  
Vol 66 (suppl_1) ◽  
Author(s):  
Jamal Bajwa ◽  
Lakshmi Pulakat

Myeloid Cell Leukemia I (MCL-1) is a critical protein for neuronal cell survival. MCL-1 is one of the anti-apoptotic proteins in the Bcl2 family. In neurons, MCL-1 regulates the rate of programmed cell death during development and after neuronal damage. It is now well established that without sufficient MCL-1 dopaminergic neuronal cells succumb to cell death under conditions of oxidative stress that result in neurodegenerative diseases such as Parkinsonism. Therefore, identifying drugs that can up-regulate the expression of MCL-1 in neuronal cells is critical for enhancing neuronal resistance to oxidative stress and improving neuronal survival. Aim of this study was to evaluate the effects of treatments with Rapamycin and a novel AT2R peptide agonist NP-6A4 on the MCL-1 expression in SH-SY5Y neuronal cell line. SH-SY5Y cells are a human-derived in vitro model of neuronal function and differentiation, expressing both adrenergic and dopaminergic markers. This cell line is a highly translational model for Parkinson's disease. Cells were maintained in a 1:1 mixture of DMEM and Ham's F-12 with 10% FBS. Cells were subjected to serum starvation and were treated with Rap (10nM), NP-6A4 (300nM) or their combination for 6 hours. MCL-1 protein expression was assessed by immunofluorescence using anti-MCL-1 antibody and a fluorophore-conjugated secondary antibody. Cells were imaged using a confocal microscope and fluorescence was quantified using Leica LAS AF software. It was observed that Rap treatment significantly suppressed MCL-1 expression in SH-SY5Y cells (~40% suppression, p<0.001), whereas Rap+NP-6A4 treatment reversed the Rap-mediated suppression of MCL-1 (p<0.0002). This data indicates that Rapamycin suppresses MCL-1 in dopaminergic neuronal cells and AT2R agonist, NP-6A4 is capable of reversing this effect.


Sign in / Sign up

Export Citation Format

Share Document